[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2117038T3 - Derivados de indolina que llevan una funcion amidica, su preparacion, las composiciones farmaceuticas que los contienen. - Google Patents

Derivados de indolina que llevan una funcion amidica, su preparacion, las composiciones farmaceuticas que los contienen.

Info

Publication number
ES2117038T3
ES2117038T3 ES92402213T ES92402213T ES2117038T3 ES 2117038 T3 ES2117038 T3 ES 2117038T3 ES 92402213 T ES92402213 T ES 92402213T ES 92402213 T ES92402213 T ES 92402213T ES 2117038 T3 ES2117038 T3 ES 2117038T3
Authority
ES
Spain
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92402213T
Other languages
English (en)
Inventor
Jean Wagnon
Claudine Serradeil-Legal
Bernard Tonnerre
Claude Plouzane
Dino Nisato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of ES2117038T3 publication Critical patent/ES2117038T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) EN LA QUE UN HIDROXILO, UN ALCOXI EN C1-C4, UN GRUPO BENCILOXI, CIANO, TRIFLUOROMETILO, NITRO O AMINO; -R2 REPRESENTA UN ALQUILO EN C1-C6, UN CICLOALQUILO EN C3-C7, UN CICLOACENO EN C5-C7, UN FENILO NO SUSTITUIDO UNA O VARIAS VECES, UN ALCOXI EN C1-C4, UN HALOGENO, UN GRUPO TRIFLUOROMETILO, UN GRUPO AMINO, O R2 REPRESENTA UN NITROFENILO NO SUSTITUIDO O SUSTITUIDO UNA O VARIAS VECES; GRUPO CARBAMOILO DE FORMULA CONR6R7; 1; UN FENILO NO SUSTITUIDO O SUSTITUIDO UNA O VARIAS VECES, O R5 REPRESENTA UN NITROFENILO NO SUSTITUIDO O SUSTITUIDO UNA O VARIAS VECES; ILAR A R7; ZETIDIN-3-IL, ESTANDO SUSTITUIDOS O NO DICHOS GRUPOS SOBRE EL NITROGENO POR UN ALQUILO EN C1-C4, POR UN BENCILOXICARBONILO O POR UN ALCOXICARBONILO EN C1-C4; UN GRUPO (CH2)R EL MISMO SUSTITUIDO POR UN GRUPO PIRIDIL -2, -3 O -4, POR UN GRUPO HIDROXILO, POR UN GRUPO AMINO LIBRE O SUSTITUIDO POR UNO O DOS SUSTITUYENTES, NO AL QUE ESTAN LIGADOS UN HETEORCICLO ELEGIDO ENTRE: . LA MORFOLINA, . LA TIOMORFOLINA, . LA TIAZOLIDINA O LA 2,2-DIMETILTIAZOLIDINA NO SUSTITUIDAS O SUSTITUIDAS POR R8, . LA PIPERACINA NO SUSTITUIDA O SUSTITUIDA EN 4 POR UN GRUPO R"8, . UN CICLO INSATURADO MONONITROSO CON 5 ESLABONES SUSTITUIDO POR R8 O UN CICLO SATURADO MONONITROSO DE 3,4,5,6, O 7 ESLABONES SUSTITUIDO POR R8 Y R9; STITUIDO POR UN GRUPO CARBOXILO, UN GRUPO ALCOXICARBONILO EN C1-C4, UN GRUPO BENCILOXICARBONILO, UN GRUPO CARBAMOILO LIBRE O SUSTITUIDO POR UN HIDROXILO O POR UNO O DOS ALQUILOS EN C1-C4, O UN GRUPO AMINOCARBOTIOILO LIBRE O SUSTITUIDO POR UNO O DOS ALQUILOS EN C1C4; RE O SUSTITUIDO POR UNO O DOS ALQUILOS EN C1-C4; TA HIDROGENO, UN HALOGENO, UN GRUPO (CH2)R OR10, UN GRUPO (CH2)R NR11 R12, UN GRUPO (CH2)S CONR11 R''11, UN GRUPO ACIDO; REPRESENTA HIDROGENO, UN ALQUILO EN C1-C4, UN MESILO O UN TOSILO; ALQUILO EN C1-C4 O R11 REPRESENTA HIDROGENO Y R12 REPRESENTA UN BENCILOXICABONILO O UN ALCOXICARBONILO EN C1-C4; TA 0, 1 O 2; - R REPRESENTA 0, 1, 2 O 3 CON LA LIMITACION QUE R NO ES NULO CUANDO R8 O R9 ESTA EN POSICION ALFA DEL NITROGENO AMIDICO INTRACICLICO; ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE LAS AFECCIONES DEL SISTEMA NERVIOSO CENTRAL, DE SISTEMA CARDIOVASCULAR Y DE LA ESFERA GASTRICA EN EL HOMBRE Y EN LOS ANIMALES.
ES92402213T 1991-08-02 1992-08-03 Derivados de indolina que llevan una funcion amidica, su preparacion, las composiciones farmaceuticas que los contienen. Expired - Lifetime ES2117038T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (fr) 1991-08-02 1991-08-02 Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.

Publications (1)

Publication Number Publication Date
ES2117038T3 true ES2117038T3 (es) 1998-08-01

Family

ID=9415909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92402213T Expired - Lifetime ES2117038T3 (es) 1991-08-02 1992-08-03 Derivados de indolina que llevan una funcion amidica, su preparacion, las composiciones farmaceuticas que los contienen.

Country Status (29)

Country Link
EP (1) EP0526348B1 (es)
JP (1) JP2633085B2 (es)
KR (1) KR100241583B1 (es)
AT (1) ATE163289T1 (es)
AU (2) AU658664B2 (es)
BR (1) BR9205336A (es)
CA (2) CA2206776C (es)
CZ (1) CZ288173B6 (es)
DE (1) DE69224450T2 (es)
DK (1) DK0526348T3 (es)
ES (1) ES2117038T3 (es)
FI (2) FI104069B (es)
FR (1) FR2679903B1 (es)
HK (1) HK1008741A1 (es)
HU (2) HUT68927A (es)
IL (3) IL117592A (es)
LT (1) LT3064B (es)
LV (1) LV10091B (es)
MX (1) MX9204487A (es)
MY (1) MY110517A (es)
NO (1) NO180047C (es)
NZ (1) NZ243795A (es)
PH (1) PH30661A (es)
RU (1) RU2104268C1 (es)
SG (1) SG47501A1 (es)
SK (1) SK283463B6 (es)
UA (1) UA27238C2 (es)
WO (1) WO1993003013A1 (es)
ZA (1) ZA925781B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999006437A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
AU8585098A (en) * 1997-07-31 1999-02-22 American Home Products Corporation Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999006433A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
FR2775598A1 (fr) * 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
IL143928A0 (en) 1999-01-22 2002-04-21 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
NZ529822A (en) 1999-01-22 2005-11-25 Elan Pharm Inc Acyl derivatives which treat VLA-4 related disorders
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2792834A1 (fr) * 1999-04-29 2000-11-03 Sanofi Sa Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
FR2805536B1 (fr) * 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805992A1 (fr) * 2000-03-08 2001-09-14 Sanofi Synthelabo Compositions pharmaceutiques orales contenant des derives de n-sulfonylindoline
CA2423933A1 (en) 2000-10-17 2002-04-25 Applied Research Systems Ars Holding N.V. Pharmaceutically active sulfanilide derivatives
AU2002224115A1 (en) 2000-11-28 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. 1,4,5,6-tetrahydroimidazo(4,5-d)diazepine derivatives or salts thereof
JP4044740B2 (ja) * 2001-05-31 2008-02-06 信越化学工業株式会社 レジスト材料及びパターン形成方法
ATE311185T1 (de) 2001-12-20 2005-12-15 Applied Research Systems Triazole als oxytocin-antagonisten
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2485681C (en) * 2002-05-24 2012-10-16 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
BR0315115A (pt) * 2002-10-11 2005-08-16 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
ATE363470T1 (de) 2002-11-18 2007-06-15 Chemocentryx Inc Arylsulfonamide
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
BRPI0616687A2 (pt) 2005-09-29 2011-06-28 Elan Pharm Inc compostos de pirimidinil amida que inibem a adesão leucocitária mediada por vla-4
CA2851103A1 (en) 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
NZ570679A (en) 2006-02-27 2011-01-28 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated By VLA-4
MX2011011326A (es) 2009-04-27 2012-02-13 Elan Pharm Inc Antagonistas de piridinona de las integrinas alfa-4.
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
BR9205336A (pt) 1993-11-16
JP2633085B2 (ja) 1997-07-23
NO180047C (no) 1997-02-05
CZ68293A3 (en) 1994-01-19
NO931262L (no) 1993-05-26
CA2093221C (en) 1998-09-22
SK42693A3 (en) 1993-10-06
IL117592A0 (en) 1996-07-23
DE69224450D1 (de) 1998-03-26
FI980175A0 (fi) 1998-01-27
IL117592A (en) 1999-04-11
HU211884A9 (en) 1995-12-28
FR2679903B1 (fr) 1993-12-03
AU658664B2 (en) 1995-04-27
NZ243795A (en) 1995-04-27
SG47501A1 (en) 1998-04-17
RU2104268C1 (ru) 1998-02-10
CA2206776C (en) 2002-02-26
FR2679903A1 (fr) 1993-02-05
FI980175A (fi) 1998-01-27
LV10091A (lv) 1994-05-10
SK283463B6 (sk) 2003-08-05
CA2206776A1 (en) 1993-02-03
DE69224450T2 (de) 1998-07-30
CZ288173B6 (en) 2001-05-16
EP0526348B1 (fr) 1998-02-18
FI104069B1 (fi) 1999-11-15
NO180047B (no) 1996-10-28
WO1993003013A1 (fr) 1993-02-18
AU1154195A (en) 1995-05-04
IL102703A (en) 1997-03-18
PH30661A (en) 1997-09-16
LV10091B (en) 1995-04-20
FI104069B (fi) 1999-11-15
FI107048B (fi) 2001-05-31
CA2093221A1 (en) 1993-02-03
IL102703A0 (en) 1993-01-14
ZA925781B (en) 1993-03-02
NO931262D0 (no) 1993-04-01
AU691223B2 (en) 1998-05-14
ATE163289T1 (de) 1998-03-15
FI931476A (fi) 1993-04-01
EP0526348A1 (fr) 1993-02-03
FI931476A0 (fi) 1993-04-01
JPH06501960A (ja) 1994-03-03
MX9204487A (es) 1993-02-01
KR100241583B1 (ko) 2000-03-02
HUT68927A (en) 1995-08-28
LTIP114A (en) 1994-06-15
HU9300951D0 (en) 1993-06-28
AU2475892A (en) 1993-03-02
HK1008741A1 (en) 1999-05-14
DK0526348T3 (da) 1998-11-23
LT3064B (en) 1994-10-25
UA27238C2 (uk) 2000-08-15
MY110517A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
ES2117038T3 (es) Derivados de indolina que llevan una funcion amidica, su preparacion, las composiciones farmaceuticas que los contienen.
NO914528D0 (no) N-substituerte heterocykliske derivater, deres fremstilling og farmasoeytiske preparater som inneholder dem
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
PT81748A (en) Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof
HUP9901630A2 (hu) Új indol-2,3-dion-3-oxim-származékok
HUP0002330A2 (hu) Azetidinilpropilpiperidin-származékok, ezek intermedierjei és tachikinin antagonistaként történő alkalmazásuk
HUP0100680A2 (hu) Indolszármazékok és azokat tartalmazó gyógyszerkészítmények
IE36710B1 (en) Hydrazinopyridazine derivatives
KR880005927A (ko) 카복실산 아미드의 용도
TW197420B (es)
EA200701248A1 (ru) Новые спиротропановые соединения и способы модуляции активности рецептора хемокина
CO5040081A1 (es) Nuevos compuestos vidad farmaaceutica
HUP9902606A2 (hu) Mátrix metalloproteináz inhibitorok
GB1505848A (en) 3,4-dicarboxycephalosporins and derivatives
DE1906194A1 (en) Antibiotic cephalosporin cpds.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526348

Country of ref document: ES